遺傳毒性物質(zhì)亞硝胺類(lèi)雜質(zhì)是近年來(lái)化學(xué)藥品質(zhì)量控制重點(diǎn)關(guān)注和檢驗(yàn)指標(biāo)之一。對(duì)比分析中國(guó)、歐盟、美國(guó)等藥品監(jiān)管機(jī)構(gòu)對(duì)亞硝胺雜質(zhì)的監(jiān)管策略，分析各藥品監(jiān)管部門(mén)的監(jiān)管機(jī)構(gòu)的亞硝胺雜質(zhì)檢驗(yàn)技術(shù)研究與應(yīng)用進(jìn)展，提出應(yīng)加強(qiáng)亞硝胺雜質(zhì)來(lái)源的監(jiān)管科學(xué)研究、完善基于風(fēng)險(xiǎn)評(píng)估的監(jiān)管策略、強(qiáng)化監(jiān)管機(jī)構(gòu)間監(jiān)管策略和標(biāo)準(zhǔn)的協(xié)調(diào)、加快檢驗(yàn)技術(shù)開(kāi)發(fā)和利用好抽樣檢驗(yàn)監(jiān)管手段保障藥品供應(yīng)鏈安全，為做好我國(guó)化學(xué)藥品質(zhì)量控制提供參考。

Genotoxic substances-nitrosamine impurity are one of the key inspection indicators for chemical drug quality control in recent years. The China, European and USA drug regulatory authorities present supervision strategies of nitrosamine impurities were studied, and the research advance of nitrosamine impurity inspection technology in each drug administration authority was analyzed. It was put forward that the regulatory scientific research on nitrosamine impurities must be strengthened, regulatory strategies based on risk assessment should be improved, regulatory strategies and standards coordination among drug regulatory authorities was supposed to be strengthened, the development of inspection technology ought to be accelerated, drug sampling and testing methods should be utilized to ensure the security of the pharmaceutical supply chain, so as to provide reference for chemical drug quality control in China.

R927.11

國(guó)家重點(diǎn)研發(fā)計(jì)劃課題（2018YFC0830802）；中國(guó)食品藥品檢定研究院中青年發(fā)展研究基金資助項(xiàng)目（2022G1）